Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1357634 | 1.00 | ALDH1A1 (0.49) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL5485878 | 0.96 | ALDH1A1 (0.46) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL19075663 | 0.84 | RIPK1 (0.51) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL19083795 | 0.83 | TP53 (0.36) | MAPT | |
| SCHEMBL29022329 | 0.83 | USP2 (0.40) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL29022331 | 0.83 | USP2 (0.40) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 | |
| SCHEMBL17457535 | 0.82 | PEPD (0.33) | — | |
| SCHEMBL5314180 | 0.80 | RIPK1 (0.33) | — | |
| SCHEMBL3852873 | 0.80 | RIPK1 (0.33) | — | |
| SCHEMBL17069042 | 0.80 | ALDH1A1 (0.50) | ALDH1A1TSHRKMT2AMEN1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021149814-A1 | CATALYST FOR MANUFACTURING AMIDE COMPOUND, AND METHOD FOR MANUFACTURING AMIDE COMPOUND | 学校法人中部大学 | 2021-07-29 | — | — | WO | disclosed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| EP-2253614-B1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-09-19 | — | — | EP | disclosed |
| EP-1735307-B1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2012-08-29 | — | — | EP | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-8207183-B2 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| US-20110281875-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| EP-2253614-A1 | Inhibitors of IAP | Novartis AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | SEDELMEIER GOTTFRIED | 2010-07-22 | — | — | US | disclosed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-20080200687-A1 | Preparation of Terazole Derivatives | SEDELMEIER GOTTFRIED | 2008-08-21 | — | — | US | disclosed |
| EP-1907378-A1 | PREPARATION OF TERAZOLE DERIVATIVES | Novartis AG (CH) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007009716-A1 | PREPARATION OF TERAZOLE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| EP-1735307-A1 | INHIBITORS OF IAP | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097791-A1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| US-20050234042-A1 | Organic compounds | PALERMO MARK G | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | ALDH1A1 4526/4885TSHR 4426/4885KMT2A 4593/4885 |
| US-20080200687-A1 | Preparation of Terazole Derivatives | TERB1, TALDO1, TERT | ALDH1A1 812/4885TSHR 176/4885KMT2A 3778/4885 |
| US-20100184991-A1 | PREPARATION OF TERAZOLE DERIVATIVES | TERB1, TALDO1, TERT | ALDH1A1 812/4885TSHR 176/4885KMT2A 3778/4885 |
| US-20110281875-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | ALDH1A1 4329/4885TSHR 4589/4885KMT2A 4431/4885 |
| US-20050234042-A1 | Organic compounds | AIFM1, BAX, API5 | ALDH1A1 3393/4885TSHR 4805/4885KMT2A 4258/4885 |
| US-20120207769-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | ALDH1A1 4329/4885TSHR 4589/4885KMT2A 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.